arginylarginine has been researched along with prolyl-proline in 2 studies
| Studies (arginylarginine) | Trials (arginylarginine) | Recent Studies (post-2010) (arginylarginine) | Studies (prolyl-proline) | Trials (prolyl-proline) | Recent Studies (post-2010) (prolyl-proline) |
|---|---|---|---|---|---|
| 19 | 1 | 9 | 40 | 0 | 20 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faria, TN; Quan, Y; Smith, RL; Stouch, TR; Timoszyk, JK; Vig, BS; Wall, DA | 1 |
| Abdelgader, EA; Abdelrahim, SO; Altayeb, OA; Babekir, EA; Eltayeb, NH; Fadul, EA; Ibrahim, IK; Mohammed Basabaeen, AA; Sabo, A | 1 |
2 other study(ies) available for arginylarginine and prolyl-proline
| Article | Year |
|---|---|
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
Topics: Animals; Binding Sites; Biological Transport; Cell Line; Dipeptides; Dogs; Electricity; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Peptide Transporter 1; Proline; Protein Binding; Protein Conformation; Structure-Activity Relationship; Symporters | 2006 |
TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population
Topics: Adult; Aged; Aged, 80 and over; Alleles; Case-Control Studies; Codon; Dipeptides; Female; Genetic Predisposition to Disease; Genotype; Homozygote; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Single Nucleotide; Sudan; Tumor Suppressor Protein p53; Young Adult | 2019 |